Effect of Procalcitonin Testing on Health-care Utilization and Costs in Critically Ill Patients in the United States

Chest

Volumn 151, Issue 1, 2017, Pages 23-33

  Balk, Robert A ^a   Kadri, Sameer S ^f   Cao, Zhun ^e   Robinson, Scott B ^e   Lipkin, Craig ^e   Bozzette, Samuel A ^b,c,d  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b Medical Affairs Americas East Asia and Global Health Economics and Outcomes   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e Premier Healthcare Alliance   (United States)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

antibiotic use; cost of care; intensive care unit; procalcitonin; sepsis

Indexed keywords

ANTIBIOTIC AGENT; PROCALCITONIN; BONE DENSITY CONSERVATION AGENT; CALCITONIN;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DATA BASE; DIAGNOSTIC TEST; DISEASE ASSOCIATION; DRUG COST; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITAL DISCHARGE; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PROPENSITY SCORE; RETROSPECTIVE STUDY; SEPSIS; UNITED STATES; CLINICAL CHEMISTRY; COST BENEFIT ANALYSIS; CRITICAL ILLNESS; DEMOGRAPHY; MIDDLE AGED; PROCEDURES; SOCIOECONOMICS; STATISTICS AND NUMERICAL DATA;

AGED; BONE DENSITY CONSERVATION AGENTS; CALCITONIN; CLINICAL CHEMISTRY TESTS; COST-BENEFIT ANALYSIS; CRITICAL ILLNESS; DEMOGRAPHY; FEMALE; HUMANS; INTENSIVE CARE UNITS; LENGTH OF STAY; MALE; MIDDLE AGED; PROPENSITY SCORE; RETROSPECTIVE STUDIES; SEPSIS; SOCIOECONOMIC FACTORS; UNITED STATES;

EID: 85009773445     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1016/j.chest.2016.06.046     Document Type: Article

References (35)

1. 1 Torio CM, Andrews RM. National Inpatient Hospital Costs: The Most Expensive Conditions by Payer, 2011. HCUP Statistical Brief #160. Rockville, MD: Agency for Healthcare Research and Quality; August 2013.
2. 2 Vincent, J.L., Rello, J., Marshall, J., et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 302:21 (2009), 2323–2329.
3. 3 Kaukonen, K.M., Bailey, M., Pilcher, D., et al. Systemic inflammatory response syndrome criteria in defining severe sepsis. N Engl J Med 372:17 (2015), 1629–1638.
4. 4 Kumar, A., Roberts, D., Wood, K.E., et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 34:6 (2006), 1589–1596.
5. 5 Zilberberg, M.D., Shorr, A.F., Micek, S.T., et al. Multi-drug resistance, inappropriate initial antibiotic therapy and mortality in Gram-negative severe sepsis and septic shock: a retrospective cohort study. Crit Care, 18(6), 2014, 596.
6. 6 Schuetz, P., Chiappa, V., Briel, M., Greenwald, J.L., Procalcitonin algorithms for antibiotic therapy decisions: a systematic review of randomized controlled trials and recommendations for clinical algorithms. Arch Intern Med 171:15 (2011), 1322–1331.
7. 7 Assicot, M., Gendrel, D., Carsin, H., et al. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 341:8844 (1993), 515–518.
8. 8 Simon, L., Gauvin, F., Amre, D.K., et al. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 39:2 (2004), 206–217.
9. 9 Kip, M.M., Kusters, R., Izerman, M.J., Steuten, L.M., A PCT algorithm for discontinuation of antibiotic therapy is a cost-effective way to reduce antibiotic exposure in adult intensive care patients with sepsis. J Med Econ 18:11 (2015), 944–953.
10. 10 Bouadma, L., Luyt, C.E., Tubach, F., et al. Use of procalcitonin to reduce patients’ exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet 375:9713 (2010), 463–474.
11. 11 Hochreiter, M., Kohler, T., Schweiger, A.M., et al. Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial. Crit Care, 13(3), 2009, R83.
12. 12 Nobre, V., Harbarth, S., Graf, J.D., et al. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med 177:5 (2008), 498–505.
13. 13 Christ-Crain, M., Jaccard-Stolz, D., Bingisser, R., et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 363:9409 (2004), 600–607.
14. 14 Shehabi, Y., Sterba, M., Garrett, P.M., et al. Procalcitonin algorithm in critically ill adults with undifferentiated infection or suspected sepsis. A randomized controlled trial. Am J Respir Crit Care Med 190:10 (2014), 1102–1110.
15. 15 Schuetz, P., Christ-Crain, M., Thomann, R., et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 302:10 (2009), 1059–1066.
16. 16 Dellinger, R.P., Levy, M.M., Rhodes, A., et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 41:2 (2013), 580–637.
17. 17 Rosenbaum, P.R., Rubin, D.B., The central role of the propensity score in observational studies for causal effects. Biometrika 70:1 (1983), 41–55.
18. 18 Austin, P.C., Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 28:25 (2009), 3083–3107.
19. 19 Austin, P.C., Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Communications in Statistics Simulation Computation 38:6 (2009), 1228–1234.
20. 20 Kroch EA, Duan M. CareScience Risk Assessment Model—Hospital Performance Measurement, Presentations from a November 2008 meeting to discuss issues related to mortality measures. http://archive.ahrq.gov/professionals/quality-patient-safety/quality-resources/tools/mortality/KrochRisk.html. Accessed January 15, 2016.
21. 21 Li Z, Mahendra G. Using “Recycled Predictions” for Computing Marginal Effects, Statistics and Data Analysis, SAS Global Forum 2010, Paper 272-2010. http://support.sas.com/resources/papers/proceedings10/272-2010.pdf. Accessed January 12, 2016.
22. 22 American Hospital Association Website. https://www.ahadataviewer.com/quickreport/A_Summary_View_Of_United_States_Hospitals_Preview.pdf. Accessed March 18, 2016.
23. 23 Cohen, J., Vincent, J.L., Adhikari, N.K., et al. Sepsis roadmap for future research. Lancet Infect Dis 15:5 (2015), 581–614.
24. 24 Heyland, D.K., Johnson, A.P., Reynolds, S.C., Muscedere, J., Procalcitonin for reduced antibiotic exposure in the critical care setting: a systematic review and an economic evaluation. Crit Care Med 39:7 (2011), 1792–1799.
25. 25 Kopterides, P., Siempos II, Tsangaris, I., et al. Procalcitonin-guided algorithms of antibiotic therapy in the intensive care unit: a systematic review and meta-analysis of randomized controlled trials. Crit Care Med 38:11 (2010), 2229–2241.
26. 26 Schuetz, P., Briel, M., Mueller, B., Clinical outcomes associated with procalcitonin algorithms to guide antibiotic therapy in respiratory tract infections. JAMA 309:7 (2013), 717–718.
27. 27 Westwood, M., Ramackers, B., Whiting, P., et al. Procalcitonin testing to guide antibiotic therapy for the treatment of sepsis in intensive care settings and for suspected bacterial infection in emergency department settings: a systematic review and cost-effectiveness analysis. Health Technol Assess 19:96 (2015), 1–236.
28. 28 Soni, N.J., Samson, D.J., Galaydick, J.L., et al. Procalcitonin-guided antibiotic therapy: a systematic review and meta-analysis. J Hosp Med 8:9 (2013), 530–540.
29. 29 Schuetz, P., Balk, R., Briel, M., et al. Economic evaluation of procalcitonin-guided antibiotic therapy in acute respiratory infections: a US health system perspective. Clin Chem Lab Med 53:4 (2015), 583–592.
30. 30 Prkno, A., Wacker, C., Brunkhorst, F.M., Schlattmann, P., Procalcitonin-guided therapy in intensive care unit patients with severe sepsis and septic shock—a systematic review and meta-analysis. Crit Care, 17(6), 2013, R291.
31. 31 Waechter, J., Kumar, A., Lapinsky, S.E., et al. Interaction between fluids and vasoactive agents on mortality in septic shock: a multicenter, observational study. Crit Care Med 42:10 (2014), 2158–2168.
32. 32 Mouncey, P.R., Osborn, T.M., Power, G.S., et al. Trial of early, goal-directed resuscitation for septic shock. N Engl J Med 372:14 (2015), 1301–1311.
33. 33 The ARISE Investigators and the ANZICS Clinical Trials Group. Goal-directed resuscitation for patients with early septic shock. N Engl J Med 371:16 (2014), 1496–1506.
34. 34 The ProCESS Investigators. A randomized trial of protocol-based care for early septic shock. N Engl J Med 370:18 (2014), 1683–1693.
35. 35 Levy, M.M., Rhodes, A., Phillips, G.S., et al. Surviving sepsis campaign: association between performance metrics and outcomes in a 7.5 year study. Crit Care Med 43:1 (2015), 3–12.